Objective:To evaluate roles of IL-23 in HDM-induced allergic asthma model, particularly during the allergen sensitization period
Methods: BALB/c mice were repeatedly administered with HDM intra-nasally, to develop acute allergic asthma model. Anti-IL-23p19 antibody was given during HDM sensitization period. And we analyzed the activation of DC in LDLN after last sensitization. In addition, to evaluate the roles of IL-23 at bronchial epithelium contacted with HDM, in vitro BEAS-2B cell experiments were done with HDM stimulation and/or anti-IL23 antibody treatment.
Results: Anti-IL-23 antibody treatment during allergen sensitization significantly diminished several phenotypes of allergic asthma; particularly, eosinophilic inflammation and airway hyperresponsiveness were markedly reduced. In bronchoalveolar lavage fluid, IL-4, IL-5, and IL-17A cytokine levels were significantly reduced in anti-IL-23 antibody treated mice. And the activation of DC in LDLN was significantly reduced by anti-IL-23 after last sensitization. In in vitro study, anti-IL-23 treatment prevented pro-inflammatory and pro-allergic cytokine responses in HDM-stimulated BEAS-2B cells.
Conclusion: IL-23 may play a significant role in allergic asthma during allergen sensitization period. Particularly, it may be significantly involved in allergen-contacted epithelial cell responses finally leading to allergic sensitization.